CIK 0001017491
SEEL SEELOS THERAPEUTICS, INC.
Insider trading from SEC Form 4. Last filing Mar 1, 2024.
In brief
SEELOS THERAPEUTICS, INC. (SEEL) has 9 SEC Form 4 filings on file from 6 insiders, the latest filed on Mar 1, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
2 open-market trades have been scored at SEEL. The newest: Michael Joseph Golembiewski (Chief Financial Officer) bought $100k of stock on Nov 30, 2023, filed Dec 1, 2023, scored 50 (moderate). 2 insiders bought within 14 days of each other around Nov 30, 2023.
Last 90 days
Signals
Open-market buys and sells at SEELOS THERAPEUTICS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Michael Joseph Golembiewski Chief Financial Officer buy | $100k 83,000 shares | +2406% | - | |
| 43Moderate | Raj Mehra See Remarks buy | $100k 75,757 shares | +69% | - |
Transactions
Every row filed, 10 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 29, 2024 | Michael Joseph Golembiewski Chief Financial Officer | AGrant or award Common Stock | +417 | $1.10 | $457 | 86,869 | Mar 1, 2024 |
| Jan 12, 2024 | Michael Joseph Golembiewski Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +24,537 | $0.00 | $0 | 24,537 | Jan 17, 2024 |
| Jan 12, 2024 | Raj Mehra See Remarks | AGrant or award Stock Option (right to buy)derivative | +70,383 | $0.00 | $0 | 70,383 | Jan 17, 2024 |
| Jan 4, 2024 | Margaret Dalesandro director | AGrant or award Stock Option (right to buy)derivative | +1,666 | $0.00 | $0 | 1,666 | Jan 8, 2024 |
| Jan 4, 2024 | Brian Lian director | AGrant or award Stock Option (right to buy)derivative | +1,666 | $0.00 | $0 | 1,666 | Jan 8, 2024 |
| Jan 4, 2024 | Daniel J. O'Connor director | AGrant or award Stock Option (right to buy)derivative | +1,666 | $0.00 | $0 | 1,666 | Jan 8, 2024 |
| Jan 4, 2024 | Richard W Pascoe director | AGrant or award Stock Option (right to buy)derivative | +1,666 | $0.00 | $0 | 1,666 | Jan 8, 2024 |
| Dec 1, 2023 | Raj Mehra See Remarks | POpen-market purchase Common Stock | +75,757 | $1.32 | $100k | 185,142 | Dec 1, 2023 |
| Nov 30, 2023 | Michael Joseph Golembiewski Chief Financial Officer | POpen-market purchase Common Stock | +83,000 | $1.21 | $100k | 86,450 | Dec 1, 2023 |
| Dec 1, 2023 | Raj Mehra See Remarks | POpen-market purchase Common Stock Warrant (right to buy)derivative | +75,757 | - | - | 75,757 | Dec 1, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Margaret Dalesandrodirector
- Michael Joseph GolembiewskiChief Financial Officer
- Brian Lianceo, president, officer, director
- Raj MehraSee Remarks
- Daniel J. O'Connordirector, ceo, president, officer
- Richard W Pascoedirector
Questions about SEEL
Answered from the filings on this page, as of the latest one.
Are insiders buying SEEL?
No. In the last 90 days no insider at SEELOS THERAPEUTICS, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade SEEL on the open market?
Michael Joseph Golembiewski (Chief Financial Officer) bought $100k of SEEL on Nov 30, 2023 and filed the Form 4 on Dec 1, 2023. InsiderTell scored 50 (moderate), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at SEELOS THERAPEUTICS, INC.?
6 people have filed a Form 4 at SEELOS THERAPEUTICS, INC., among them Margaret Dalesandro (director), Michael Joseph Golembiewski (Chief Financial Officer), Brian Lian (CEO, president and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.